Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion InfusionsDHA:ORIONINFU +9.98%70 Equity-to-Asset is 0.40 as of Mar. 2026, which is 8% above its 10-year median of 0.37. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 70/100 and a GF Value™ of BDT312.04 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Orion Infusions ranks worse than 75.6% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Orion Infusions's Total Stockholders Equity for the quarter that ended in Mar. 2026 was BDT330.1 Mil. Orion Infusions's Total Assets for the quarter that ended in Mar. 2026 was BDT825.8 Mil.
Therefore, Orion Infusions's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.40.
The historical rank and industry rank for Orion Infusions's Equity-to-Asset or its related term are showing as below:
DHA:ORIONINFU'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.12 Med: 0.37 Max: 0.4
Current: 0.4
During the past 13 years, the highest Equity to Asset Ratio of Orion Infusions was 0.40. The lowest was 0.12. And the median was 0.37.
DHA:ORIONINFU's Equity-to-Asset is ranked worse than 75.6% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs DHA:ORIONINFU: 0.40
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Orion Infusions Equity-to-Asset Related Terms
Orion Infusions Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Orion Infusions's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONINFU vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Infusions Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Orion Infusions's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Orion Infusions's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Infusions (DHA:ORIONINFU) has a Equity-to-Asset of 0.40 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Orion Infusions and its competitors. This is near median its historical median of 0.37. Over the past decade, Orion Infusions' Equity-to-Asset has ranged from 0.12 to 0.40. According to the industry distribution chart, Orion Infusions ranks #762 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 75.6%.
Is Orion Infusions' Equity-to-Asset too high?
Orion Infusions' current Equity-to-Asset of 0.40 is near median its 10-year median of 0.37. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 0.40. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Orion Infusions' value of 0.40 is 33.3% below this industry median. Based on the distribution chart, Orion Infusions ranks #762 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orion Infusions has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #762 out of 1008 companies for Equity-to-Asset. This places Orion Infusions in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Orion Infusions' value of 0.40 is 33.3% below this benchmark. Historically, Orion Infusions' own Equity-to-Asset has ranged from 0.12 to 0.40 over the past decade. While the company's 10-year median is 0.37 vs. the industry median of 0.60, Orion Infusions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Infusions's current Equity-to-Asset of 0.40 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Orion Infusions and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current Equity-to-Asset is 0.40, which is near median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Significantly Undervalued. The stock's GF Value™ is BDT312.04, compared to a current price of BDT213.70 — trading 31.5% below its estimated fair value. The current Equity-to-Asset is 0.40, which is near median its 10-year median of 0.37 and 33.3% below the Drug Manufacturers industry median of 0.60. Orion Infusions' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current Equity-to-Asset is 0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT213.70 is trading 31.5% below its estimated GF Value™ of BDT312.04.
GuruFocus considers Orion Infusions to be Significantly Undervalued.
Key valuation signals for DHA:ORIONINFU:
Equity-to-Asset: 0.40 (near median its 10-year median of 0.37)
GF Value™: BDT312.04 vs. price of BDT213.70 (31.5% below fair value)
Industry Position: 33.3% below the Drug Manufacturers median (#762 of 1008)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
70GF Score
Get the complete analysis for DHA:ORIONINFU
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
